ESC Heart Failure

Article	Citations
Corrigendum	87
	80
Right ventricular strain predicts outcome in patients receiving sacubitril/valsartan: A sub‐analysis of DISCOVER‐ARNI	71
Calcium channel blockers and clinical outcomes in patients with continuous‐flow left ventricular assist devices	68
Establishing a novel model to assess exercise capacity in chronic heart failure based on stress echocardiography	67
Different activation of MAPKs and Akt/GSK3β after preload vs. afterload elevation	65
Systolic dysfunction and mortality in critically ill patients: more data are needed to believe in this association!	60
Impact of age on characteristics, performance measures and outcomes of inpatients for heart failure in Beijing, China	57
Blood perfusion status is important in the prognosis of ventricular aneurysm complicated by ventricular septal rupture	55
Editors' highlight picks from 2023 in ESC heart failure	54
Characteristics and management of very elderly patients with heart failure: a retrospective, population cohort study	48
Acylation‐stimulating protein and heart failure progression in arrhythmogenic right ventricular cardiomyopathy	45
Atrial fibrillation ablation in patients with arrhythmia‐induced cardiomyopathy: a prospective multicentre study	45
Biomarker profiles in heart failure with preserved vs. reduced ejection fraction: results from the DIAST‐CHF study	44
Models of cardiovascular surgery biobanking to facilitate translational research and precision medicine	44
New insight: particle flow rate from the airways as an indicator of cardiac failure in the intensive care unit	43
Impact of early intensive GDMT on LVEF recovery and ICD decision making in de novo HFrEF	43
Clinical course of patients with hypertrophic cardiomyopathy away from tertiary referral care	42
Global differences in acute heart failure treatment: analysis of the STRONG‐HF site feasibility questionnaire	42
Synchronized diaphragmatic stimulation: a case report of a novel extra‐cardiac intervention for chronic heart failure	41
Early achievement of walkability after cardiac surgery and the risk of cardiovascular disease after hospital discharge	41
Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan	41
Burden of hospitalizations in newly diagnosed heart failure patients in Poland: real world population based study in years 2013–2019	40
The use of MitraClip for nonobstructive hypertrophic cardiomyopathy with mixed severe mitral valve regurgitation	40
Issue Information	39

Cardiogenic shock requiring VA‐ECMO therapy in scorpionism‐induced myocarditis	39
Circ_0001206 regulates miR‐665/CRKL axis to alleviate hypoxia/reoxygenation‐induced cardiomyocyte injury in myocardial infarction	38
Uncovering the genetic links of SARS‐CoV‐2 infections on heart failure co‐morbidity by a systems biology approach	38
Intense optimization of oral therapy rapidly restores respiratory function in worsening heart failure patients	38
Predictive value of global longitudinal strain by left ventricular ejection fraction	38
Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance	37
Health‐related quality of life among transthyretin amyloid cardiomyopathy patients	36
Assessing the link of malnutrition with diabetes and mortality risk in heart failure patients	36
Long‐term outcomes of electrical storm patients listed for urgent heart transplantation but not transplanted acutely	35
Oral milrinone for management of refractory right ventricular failure in patients with left ventricular assist devices	35
	35
Analysis of the serum levels of RIP3 and Drp1 in patients with heart failure	35
Risk classification for long‐term mortality among patients with acute heart failure: China PEACE 4YMortality	35
Real‐time pulmonary artery pressure monitoring in heart failure patients: an updated cost‐effectiveness analysis	35
Oral iron supplementation in patients with heart failure: a systematic review and meta‐analysis	34
Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator	34
Meta‐Analysis Global Group in Chronic Heart Failure score for the prediction of mortality in valvular heart disease	34
Prognostic value of left atrial strain in acute and chronic heart failure: A meta‐analysis	33
Explainable machine learning and online calculators to predict heart failure mortality in intensive care units	33
Percutaneous endocardial alginate–hydrogel injection in the treatment of heart failure: First‐in‐human study	33
Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry	33
Reductions in renin‐angiotensin system inhibitors following hospitalization for heart failure	32
Serum angiotensin‐converting enzyme levels indicating early sarcoidosis diagnosis and immunosuppressive therapy efficacy	32
Use of liver stiffness measurements in acute decompensated heart failure: new applications of a non‐invasive technique	32
Sex differences in the impact of frailty on patients with heart failure: A retrospective cohort study	31
Discordance between estimated and measured changes in plasma volume among patients with acute heart failure	31
Cardiac involvement in patients recovering from Delta Variant of COVID‐19: a prospective multi‐parametric MRI study	30
Effect of beta‐blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta‐analysis	30
Fibroblast growth factor 23 independently predicts adverse outcomes after an acute coronary syndrome	30
Heart failure and trimethylamine N‐oxide: time to transform a ‘gut feeling’ in a fact?	30
Systemic immune‐inflammation index as a prognostic marker for advanced chronic heart failure with renal dysfunction	30
Transcatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a systematic review and meta‐analysis	30
Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction	29
Soluble neprilysin and survival in critically ill patients	29
Integrated care for older multimorbid heart failure patients: protocol for the ESCAPE randomized trial and cohort study	29
Increased acylcarnitines in infant heart failure indicate fatty acid oxidation inhibition: towards therapeutic options?	29
Prognostic value of hypoxaemic burden from overnight oximetry in heart failure with preserved ejection fraction	29
Meta‐analysis of cardiac magnetic resonance in prognosticating left ventricular function in peripartum cardiomyopathy	29
Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator	28
Achieved dose and treatment discontinuation of candesartan in men and women with chronic heart failure: data from CHARM	28
Prognostic value of left atrial reverse remodelling in patients hospitalized with acute decompensated heart failure	28
Issue Information	28
Angiographic classification of total occlusion and its implication on balloon pulmonary angioplasty	28
Letter to the editor regarding ‘Autopsy findings in cases of fatal COVID‐19 vaccine‐induced myocarditis’	27
Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction	27
SARS‐CoV‐2‐related Multisystem Inflammatory Syndrome in Adult complicated by myocarditis and cardiogenic shock	27
Platelet count in heart failure patients undergoing left ventricular assist device	27
Correction to “Understanding the variability in red cell and plasma volume combinations can help guide management in heart failure”	27
Sex‐specific associations of cardiorespiratory fitness and galectin‐3 in the general population	27
Left ventricular reverse remodelling as a promising strategy for resolving left ventricular thrombus	27

Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross‐over trial	26
Acute myocarditis according to age: Presentation, management and early outcomes	26
Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN‐HF study	26
Cost‐utility analysis of add‐on Qili Qiangxin capsules in chronic heart failure with reduced ejection fraction in China	26
Effects of homoarginine supplementation on heart and skeletal muscle of rats with heart failure with preserved ejection fraction	25
Gender‐specific prevalence and trend of heart failure in China from 1990 to 2019	25
Adrenomedullin peptides and precursor levels in relation to haemodynamics and prognosis after heart transplantation	25
Outcomes after heart transplantation in patients with cardiac sarcoidosis	24
Clinical impact of follow‐up endomyocardial biopsy in myocarditis during or after immune‐suppressive therapy	24
Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease	24
Simultaneous vaccination against influenza and respiratory syncytial virus in high‐risk heart failure patients	24
Long‐term mortality in heart failure with mid‐range ejection fraction: systematic review and meta‐analysis	24
Proteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure	24
A prospective analysis of management and outcomes of worsening heart failure in the outpatient setting	23
Letter to the editor: Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study	23
Prognostic value of Growth differentiation factors 15 in Acute heart failure patients with preserved ejection fraction	23
Congestion, decongestion, renal function and diuretics in (ESC) heart failure	23
Determinants of left ventricular function improvement for cardiac resynchronization therapy candidates	23
Differences between cardiogenic shock related to acute decompensated heart failure and acute myocardial infarction	23
Delay in cardiology consultation after primary care physician referrals in heart failure: Clinical implications	22
Time‐domain heart rate variability features for automatic congestive heart failure prediction	22
Higher BNP/NT‐pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta‐analysis	22
Identification of molecular signatures in epicardial adipose tissue in heart failure with preserved ejection fraction	22
Takotsubo cardiomyopathy during armed conflict: A case series	22
Effects of exercise modalities on physical function and quality of life in patients with heart failure: A systematic review and network meta‐analysis	22
Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta‐analysis	22
Human epididymis protein 4 is a useful predictor of post‐operative prognosis in patients with severe aortic stenosis	22
Regional expert opinion: Management of heart failure with preserved ejection fraction in the Middle East, North Africa and Turkey	21
Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017	21
Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial	21
Importance of non‐cardiovascular comorbidities in atrial fibrillation and heart failure with preserved ejection fraction	21
Digital health in older adults for the prevention and management of cardiovascular diseases and frailty. A clinical consensus statement from the ESC Council for Cardiology Practice/Taskforce on Ger	21
Advances in device‐based treatment of heart failure with preserved ejection fraction: evidence from clinical trials	21
Adaptive versus maladaptive right ventricular remodelling	21
Transthyretin amyloid cardiomyopathy in aortic stenosis patients scheduled for transcatheter aortic valve implantation	21
Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode	21
Diabetes and treatment of chronic heart failure in a large real‐world heart failure population	20
Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge‐to‐edge mitral valve repair	20
Severe aortic insufficiency‐induced cardiogenic shock treated with left atrial VA‐ECMO and emergent valve‐in‐valve TAVR	20
Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure	20
The impact of heart failure therapy in patients with mildly reduced ejection fraction: a network meta‐analysis	20
Changes over time in patient‐reported outcomes in patients with heart failure	20
Biomarker prognostication across Universal Definition of Heart Failure stages	20
Novel mutation associated with non‐compaction ventricular myocardium: A case report	20
Sex‐based differences in referral of heart failure patients to outpatient clinics: a scoping review	20
Narrative synthesis of the effectiveness and characteristics of heart failure disease self‐management support programmes	20
Novel active fixation lead guided by electrical delay can improve response to cardiac resynchronization therapy in heart failure	20
Genotype is associated with left ventricular reverse remodelling and early events in recent‐onset dilated cardiomyopathy	20
Clinical application and immune infiltration landscape of stemness‐related genes in heart failure	19
Corrigendum	19
Tyrosine to threonine ratio was related to heart failure with reduced or mildly reduced ejection fraction	19
Temporal profiling of M‐TEER‐related complications	19
Long‐term prognosis of pure and impure tachycardiomyopathy	19
A contemporary simple risk score for prediction of severe acute kidney injury after heart transplantation	19
Letter regarding the article “Hypocapnia is an independent predictor of in‐hospital mortality in acute heart failure”	19
Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single‐centre experience	19
Biomarkers in heart failure: Traditional and emerging indicators for prognosis	19
Body mass index, frailty, and outcomes in heart failure with preserved ejection fraction	19
Early diagnosis, disease stage and prognosis in wild‐type transthyretin amyloid cardiomyopathy: The DIAMOND study	19
Response to Letter to the editor regarding ‘Discordance between estimated and measured changes in plasma volume among patients with acute heart failure’	19
The characteristic large‐scale annual analysis by gender and age in heart failure patients: cohort for 10 years in Korea	19
Diagnostic and prognostic value of the left atrial myopathy evaluation in cardiac amyloidosis using echocardiography	19
Cognitive transitions based on functional status in older adults with heart failure: a population‐based study	19
Prognostic impact of a history of cancer and atrial fibrillation in antithrombotic therapy for chronic heart failure	18
Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study	18
A meta‐analysis of the relationship between glycaemic variability and the mortality of patients with heart failure	18
E prostanoid receptor‐3 promotes oxidized low‐density lipoprotein‐induced human aortic smooth muscle cells inflammation	18
Real‐world effectiveness of targeted therapies in ATTR cardiomyopathy: A meta‐analysis integrating population‐based data	18
Efficacy and safety of digital therapeutics‐based cardiac rehabilitation in heart failure patients: a systematic review	18
Investigating the relationship between FRailty And Quality of LIfe in patients with heart faiLure and CKD (FRAIL study)	18
Novel electrocardiographic criteria may render possible the more accurate recognition of cardiac amyloidosis	18
Smartwatches in the assessment of heart failure patients in epidemiology and pathophysiology studies: A scoping review	18
Pre‐emptive treatment of heart failure exacerbations in patients managed with the HeartLogic™ algorithm	18
Impact of cardiac resynchronization therapy optimization inside a heart failure programme: a real‐world experience	18
Incidence, mortality, and predictors of acute kidney injury in patients with heart failure: a systematic review	18
Considerations for drug trials in hypertrophic cardiomyopathy	18
Predicted impact of atrial flow regulator on survival in heart failure with reduced and preserved ejection fraction	18
Five‐year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort	18
Impact of B‐lines‐guided intensive heart failure management on outcome of discharged heart failure patients with residual B‐lines	17
Prognostic impact of heart failure admission in survivors of acute myocardial infarction	17

IgM‐enriched immunoglobulin as adjuvant therapy for heart transplant after infection of left ventricular assist devices	17
Letter to the editor regarding ‘Discordance between estimated and measured changes in plasma volume among patients with acute heart failure’	17
S2I2N0–3 score predicts short‐ and long‐term mortality and morbidity in HFrEF: a post‐hoc analysis of the GUIDE‐IT trial	17
Comprehensive exploration of unexplained dyspnoea in subjects with normal ejection fraction and low natriuretic peptides	17
Cardiovascular vs. non‐cardiovascular deaths after heart failure hospitalization in young, older, and very old patients	17
The efficacy and safety of sodium‐glucose cotransporter 2 inhibitors in patients aged over 80 years with heart failure	17
Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review	17
Correction to: “Obesity and contraceptive use: impact on cardiovascular risk”	17
A nationwide study of temporal trends of cause‐specific hospital readmissions in patients with heart failure	17
Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?	17
Six‐months immunogenicity of BNT162b2 mRNA vaccine in heart transplanted and ventricle assist device‐supported patients	17
Clinical performance and quality measures for heart failure management in China: the China‐Heart Failure registry study	17
A polygenic risk score of atrial fibrillation improves prediction of lifetime risk for heart failure	17
Sodium‐glucose transporter 2 inhibitors may improve the prognosis of acute heart failure by correcting hypocapnia	17
Relationship between haemodynamic indicators and haemogram in patients with heart failure	17
Impact of the COVID‐19 pandemic on management and outcomes of patients with acute heart failure	17
Interpretation of elevated baseline concentrations and serial changes of high‐sensitivity cardiac troponin T in confirmed muscular dystrophies	17
Issue Information	16
Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: correspondence	16
Eniluracil blocks AREG signalling‐induced pro‐inflammatory fibroblasts of melanoma in heart failure	16
Atrial‐secondary tricuspid regurgitation: a better prognosis in early stage heart failure, but not in late stage	16
Issue Information	16
Prognostic implications of functional tricuspid regurgitation in asymptomatic degenerative mitral regurgitation	16
Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis	16
Clinical profile and 90 day outcomes of 10 851 heart failure patients across India: National Heart Failure Registry	16
Integrin beta‐like 1 is regulated by DNA methylation and increased in heart failure patients	16
Multiorgan characterization of inflammasome component expression in a rat model of advanced heart failure	16
Utilizing longitudinal data in assessing all‐cause mortality in patients hospitalized with heart failure	16
Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE‐HF and PRESERVED‐HF	16
Serum a‐1 antitrypsin as a novel biomarker in chronic heart failure	16
Issue Information	16
Egyptian expert opinion for the use of sodium‐glucose cotransporter‐2 inhibitors in patients with heart failure with reduced ejection fraction	15
Effects of bariatric surgery on cardiovascular‐related acute care use in patients with hypertrophic cardiomyopathy	15
Safety and efficacy of MitraClip in acutely ill (NYHA Class IV) patients with mitral regurgitation: Results from the global EXPAND study	15
Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events	15
Therapy gaps for patients with heart failure and reduced kidney function: A prospective cohort study	15
Diuretic dose is a strong prognostic factor in ambulatory patients awaiting heart transplantation	15
Low‐density lipoprotein cholesterol, erythrocyte, and platelet in heart failure with preserved ejection fraction	15
Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure	15
The association between cardiac involvement and long‐term clinical outcomes in patients with Duchenne muscular dystrophy	15
ST‐segment depression and left ventricular systolic function recovery post‐atrial fibrillation ablation in heart failure	15
Transition from asymptomatic to symptomatic systolic chronic heart failure: rationale and design of TransitionCHF	15
Correction to “Impact analysis of heart failure across European countries: an ESC‐HFA position paper” and “Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory he	15
Relationship of atrial fibrillation and N terminal pro brain natriuretic peptide in heart failure patients	15
Non‐dilated left ventricular cardiomyopathy vs. dilated cardiomyopathy: clinical background and outcomes	15
Mavacamten in real‐life practice: Initial experience at a hypertrophic cardiomyopathy centre	15
Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure	15
Susceptibility to infections and adaptive immunity in adults with heart failure	15
Effect of early intervention on short‐term prognosis of patients with myocardial injury induced by acute carbon monoxide poisoning	15
Paediatric heart transplantation during the COVID‐19 pandemic in Iran: single‐centre experience	15
The HFA‐PEFF score identifies ‘early‐HFpEF’ phenogroups associated with distinct biomarker profiles	15
Application of recommended therapies among patients with heart failure during the Syrian conflict: reality and barriers	15
A case of biopsy‐proven inflammatory dilated cardiomyopathy following heterologous mRNA‐1273 third‐dose immunization	15
Cardiac arrest caused by coronary occlusion during transcatheter aortic valve implantation: a unique cause	15
Advanced heart failure: guideline‐directed medical therapy, diuretics, inotropes, and palliative care	15
Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters	15
Trametinib alters contractility of paediatric Noonan syndrome‐associated hypertrophic myocardial tissue slices	15
Estimated pulse wave velocity and risk of new‐onset heart failure	15
Is ischaemic heart failure an autoimmune disease?	15
Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure	15
Fractional excretion of urea nitrogen can identify true worsening renal function in patients with heart failure	15
Characterization of critically ill patients with septic shock and sepsis‐associated cardiomyopathy using cardiovascular MRI	15
The favourable alliance between CardioMEMS and levosimendan in patients with advanced heart failure	15
Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild‐type transthyretin amyloid cardiomyopathy	15
Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i	14
Neutrophil‐to‐lymphocyte ratio: link to congestion, inflammation, and mortality in outpatients with heart failure	14
Two‐year outcome of ventricular assist device via a modified left atrium to aorta approach in cardiac amyloidosis	14
Safety and efficacy of up to 60 h of iv istaroxime in pre‐cardiogenic shock patients: Design of the SEISMiC trial	14
Associations between in‐hospital daily protein intake and adverse clinical outcomes in older patients with heart failure	14
Decoding cardiogenic shock: assessing shock index and its variants as prognostic indicators for in‐hospital mortality	14
Predicting 1‐year heart failure hospitalization and mortality post‐discharge from the intensive cardiac care unit	14
The double anaerobic threshold in heart failure: MECKI score database overview	14
Assessment of frailty in patients with heart failure: A new Heart Failure Frailty Score developed by Delphi consensus	14
Decreased endogenous nitric oxide production in acute decompensated heart failure with a reduced ejection fraction	14
Pre‐admission beta‐blocker therapy and outcomes in cardiogenic shock: Insights from the Altshock‐2 Registry	14
A simple staging system using biomarkers for wild‐type transthyretin amyloid cardiomyopathy in Japan	14
Dapagliflozin treatment and cardiovascular outcome in RBP4/TTRVal30Met (transthyretin cardiac amyloidosis) mice	14
Increased calcification by erythrophagocytosis in aortic valvular interstitial cells	14
Prognostic effect of systematic geriatric assessment on patients with acute heart failure	14
Multidisciplinary care: A missing solution to SGLT2 inhibitor underuse in heart failure	14
A pilot study on DNA methylation changes for non‐invasive molecular diagnostics in heart failure	14
Ten year age‐ and sex‐specific temporal trends in incidence and prevalence of heart failure in Västra Götaland, Sweden	14
In vivo fluid dynamics of the Ventura interatrial shunt device in patients with heart failure	14
Corticosteroid burst therapy in patients with acute heart failure: Design of the CORTAHF pilot study	14
Association between trimethylamine N‐oxide and prognosis of patients with acute myocardial infarction and heart failure	14
U‐shaped association between body mass index and ejection fraction in intensive care unit patients with heart failure	14
Association between central haemodynamics and renal function in advanced heart failure: a nationwide study from Sweden	14
Pressure–strain loops unveil haemodynamics behind mechanical circulatory support systems	14
Prognostic impact of beta‐blocker use by N‐terminal pro‐brain natriuretic peptide level in acute heart failure patients	14
Role of depressive symptoms in the prognosis of heart failure and its potential clinical predictors	13
Transjugular tricuspid valve‐in‐ring replacement using the novel system under three‐dimensional printing guidance	13
Risk prediction of mortality for patients with heart failure in England: observational study in primary care	13
Immune Checkpoint Inhibitors and Cardiovascular Adverse Events	13
Short‐term outcomes after sodium‐glucose cotransporter‐2 inhibitor initiation in a cohort of heart failure patients	13
Association between lactate/albumin ratio and mortality in patients with heart failure after myocardial infarction	13